

**Published Standard – No.1 – Applications (Centralised)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
1	Centralised: New MAs / Extensions	13	100%
2	Centralised – UK as Rapp: Variations / Renewals	9	100%

**Published Standard – No.1 – Applications (DCP)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
3	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 1 – Day 70)	16	100%
4	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 1 – Day 120)	21	100%
5	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 2)	27	100%
6	DCP – UK as CMS: New MAs & Variation-Extensions (Phase 1)	51	100%
7	DCP – UK as CMS: New MAs & Variation-Extensions (Phase 2)	65	100%

**Published Standard – No.1 – Applications (MRP)**

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
8	MRP – UK as RMS: New MAs (Phase 1)	12	100%
9	MRP – UK as RMS: New MAs (Phase 2)	13	100%
10	MRP – UK as CMS: New MAs (Phase 2)	18	100%
11	MRP – UK as RMS: Type IA Variations	56	100%
12	MRP – UK as RMS: Type IB & II Variations, and Renewals (Phase 1)	124	100%
13	MRP – UK as CMS: Type IB & II Variations, and Renewals (Phase 1)	303	99.7%

	<b>App Type</b>	<b>No. of Apps</b>	<b>Performance</b>
14	MRP – UK as RMS: Type IB & II Variations, and Renewals (Phase 2)	93	100%
15	MRP – UK as CMS: Type IB & II Variations, and Renewals (Phase 2)	185	99.5%

**Published Standard – No. 1 – Applications (National)**

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
16	New MAs & Variation-Extensions: <i>Initial Assessment</i>	<b>86</b>	100%		
	• 75 Day Clock	12		75	52.5
	• 90 Day Clock	74		90	89.9
17	New MAs & Variation-Extensions <i>Sign-Off</i>	<b>82</b>	100%		
	• 130 Day Clock	2		130	121.0
	• 180 Day Clock	80		180	159.0
18	New Homeopathic	<b>0</b>	-	-	-
19	Type IA Variations	<b>151</b>	100%	30	18.3
20	Type IB / II Variations: <i>Initial Assessment</i>	<b>140</b>	97.9%		
	• Type IB	105		30	23.8
	• Type II	26		60	52.9
	• Renewal	6		60	51.0
21	Type IB / II Variations: <i>Sign-Off</i>	<b>125</b>	100%		
	• Type IB	96		30	9.5
	• Type II	25		60	34.6
	• Renewals	4		60	48.0
22	Admin Variations	<b>44</b>	100%		
	• < 10 Changes	44		30	25.5
	• > 10 Changes	0		60	-
23	ATCs	<b>8</b>	100%		
	• Type A/S	6		30	29.5
	• Type B	1		50	32.0
	• Variations / Renewals	1		30	20.0
24	Batch Release	<b>3251</b>	100%	10	0.7

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
25	Specific Batch Control	<b>29</b>	<b>100%</b>		
	• No questions asked	24		10	0.9
	• Questions asked	5		20	12.2
26	AVA*	<b>7</b>	<b>71.4%</b>	45	60.4

#### Published Standard – No. 1 – Applications (Other)

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>
27	Mock-Ups	<b>573</b>	<b>99.3%</b>
28	Validation	<b>872</b>	<b>99.9%</b>
29	Issue of authorisation documentation	<b>1192</b>	<b>99.7%</b>

#### Published Standard – No. 2 – Quality of Documentation

	<b>App Type</b>	<b>Total No</b>	<b>Performance</b>
30	Authorisation Documentation	2619	<b>98.8%</b>

#### Published Standard – No. 3 – Import and Export Certificates

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
31	Applications for new products	<b>362</b>	<b>99.7%</b>	15	2.0
32	All other applications	<b>360</b>	<b>100%</b>		
	• Urgent	8		2	1.0
	• Non-Urgent	352		10	2.0
33	Export	<b>425</b>	<b>100%</b>	10	4.9

#### Published Standard – No. 4 – Public Assessment Reports

	<b>App Type</b>	<b>No of Apps</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
34	Publish link to SPC, or EMA	<b>192</b>	<b>99.5%</b>	30	2.0
35	Publish PuAR within 120 days	<b>147</b>	<b>100%</b>	120	51.0
36	Update PuAR within 60 days	<b>94</b>	<b>100%</b>	60	13.0

**Published Standard – No. 5 – Pharmacovigilance**

	<b>Task</b>	<b>No.</b>	<b>Performance</b>
37	Human, Animal & Environmental AERs	<b>7188</b>	99.8%
38	Human, Animal & Environmental AERs – Follow Up	<b>3744</b>	99.9%
39	PSURs	<b>1641</b>	99.8%
40	Inspections	<b>17</b>	100%

**Published Standard – No. 6 – Inspections**

	<b>Task</b>	<b>No.</b>	<b>Performance</b>	<b>Target Days</b>	<b>Average Days</b>
41	GMP Inspections within 3 years of last inspection**	<b>37</b>	97.3%	-	-
42	GDP inspections within 5 years of last inspection	<b>34</b>	100%	-	-
43	Send deficiency or post inspections letter	<b>69</b>	98.6%		
	• GMP	36		30	17.0
	• GDP	32			
44	Issue GMP Certificates and final inspection reports	<b>36</b>	100%		
				90	55.0
45	Send final inspection report to wholesaler site	<b>46</b>	97.8%		
46	Product defect reports	<b>38</b>	100%		
	• High risk <5 days	2			
	• Low risk <10 days	40			

**Key:**

<b>Dark Green</b> -	<b>Excellent 100%</b>
<b>Light Green</b> -	<b>Excellent, but some targets missed</b>
<b>Amber</b> -	<b>Effective</b>
<b>Red</b> -	<b>Ineffective</b>

### **Additional information about ‘ambers’ and ‘reds’**

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.

However, sometimes a performance standard may fall into the effective or ineffective category and there are a number of reasons why this may happen, e.g. high volume of applications, staff resource, complexity of applications requiring additional input, etc

\*In the case of the AVA application, this one proved to be much more complex than a ‘normal’ application and additional assessment was required. This meant that the application couldn’t be completed in the normal timeframe. Due to the low volume of applications, the overall standard fell into the ineffective category.